Sandbox g20: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) |
Gerald Chi- (talk | contribs) |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
* Cerebrospinal fluid shunt infection<ref>{{Cite journal| doi = 10.1086/425368| issn = 1537-6591| volume = 39| issue = 9| pages = 1267–1284| last1 = Tunkel| first1 = Allan R.| last2 = Hartman| first2 = Barry J.| last3 = Kaplan| first3 = Sheldon L.| last4 = Kaufman| first4 = Bruce A.| last5 = Roos| first5 = Karen L.| last6 = Scheld| first6 = W. Michael| last7 = Whitley| first7 = Richard J.| title = Practice guidelines for the management of bacterial meningitis| journal = Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America| date = 2004-11-01| pmid = 15494903}}</ref><ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref> | * Cerebrospinal fluid shunt infection<ref>{{Cite journal| doi = 10.1086/425368| issn = 1537-6591| volume = 39| issue = 9| pages = 1267–1284| last1 = Tunkel| first1 = Allan R.| last2 = Hartman| first2 = Barry J.| last3 = Kaplan| first3 = Sheldon L.| last4 = Kaufman| first4 = Bruce A.| last5 = Roos| first5 = Karen L.| last6 = Scheld| first6 = W. Michael| last7 = Whitley| first7 = Richard J.| title = Practice guidelines for the management of bacterial meningitis| journal = Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America| date = 2004-11-01| pmid = 15494903}}</ref><ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref> | ||
:* Empiric antimicrobial therapy | :* '''Empiric antimicrobial therapy''' | ||
::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h {{and}} ([[Cefepime]] 2 g IV q8h {{or}} [[Ceftazidime]] 2 g IV q8h {{or}} [[Meropenem]] 2 g IV q8h) | ::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h {{and}} ([[Cefepime]] 2 g IV q8h {{or}} [[Ceftazidime]] 2 g IV q8h {{or}} [[Meropenem]] 2 g IV q8h) | ||
:* Pathogen-directed antimicrobial therapy | |||
::* '''Enterococcus''' | |||
:::* Preferred regimen: ([[Penicillin G]] 4 MU IV q4h {{or}} [[Ampicillin]] 2 g IV q4h) {{and}} [[Gentamicin]] 1–1.7 mg/kg IV q8h | |||
::* '''Gram-negative bacilli''' | |||
:::* Preferred regimen: [[Ceftriaxone]] 2 g IV q12h {{or}} [[Cefepime]] 2 g IV q12h {{or}} [[Meropenem]] 2 g IV q8h {{or}} [[Aztreonam]] 2 g IV q6h | |||
::* '''Propionibacterium acnes''' | |||
:::* Preferred regimen: ([[Penicillin G]] 4 MU IV q4h {{or}} [[Ampicillin]] 2 g IV q4h) {{withorwithout}} [[Gentamicin]] 1–1.7 mg/kg IV q8h | |||
::* '''Staphylococcus, coagulase-negative''' | |||
:::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h {{withorwithout}} [[Rifampin]] 600 mg IV/PO q24h | |||
::* '''Staphylococcus aureus, methicillin-resistant''' | |||
:::* Preferred regimen: [[Vancomycin]] 30–45 mg/kg/day IV q8–12h {{withorwithout}} [[Rifampin]] 600 mg IV/PO q24h | |||
::* '''Staphylococcus aureus, methicillin-susceptible''' | |||
:::* Preferred regimen: ([[Nafcillin]] 2 g IV q4h {{or}} [[Oxacillin]] 2 g IV q4h) {{withorwithout}} [[Rifampin]] 600 mg IV/PO q24h | |||
::* '''Streptococcus agalactiae''' | |||
:::* Preferred regimen: ([[Penicillin G]] 4 MU IV q4h {{or}} [[Ampicillin]] 2 g IV q4h) {{and}} [[Gentamicin]] 1–1.7 mg/kg IV q8h | |||
::* '''Fungi''' | |||
:::* Preferred regimen: [[Amphotericin B]] 0.6–1.0 mg/kg IV q24h {{or}} [[Amphotericin B]] liposomal 5 mg/kg/day IV q24h | |||
==References== | |||
{{reflist}} | |||
Latest revision as of 08:18, 5 June 2015
- Empiric antimicrobial therapy
- Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h AND (Cefepime 2 g IV q8h OR Ceftazidime 2 g IV q8h OR Meropenem 2 g IV q8h)
- Pathogen-directed antimicrobial therapy
- Enterococcus
- Preferred regimen: (Penicillin G 4 MU IV q4h OR Ampicillin 2 g IV q4h) AND Gentamicin 1–1.7 mg/kg IV q8h
- Gram-negative bacilli
- Preferred regimen: Ceftriaxone 2 g IV q12h OR Cefepime 2 g IV q12h OR Meropenem 2 g IV q8h OR Aztreonam 2 g IV q6h
- Propionibacterium acnes
- Preferred regimen: (Penicillin G 4 MU IV q4h OR Ampicillin 2 g IV q4h) ± Gentamicin 1–1.7 mg/kg IV q8h
- Staphylococcus, coagulase-negative
- Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h ± Rifampin 600 mg IV/PO q24h
- Staphylococcus aureus, methicillin-resistant
- Preferred regimen: Vancomycin 30–45 mg/kg/day IV q8–12h ± Rifampin 600 mg IV/PO q24h
- Streptococcus agalactiae
- Preferred regimen: (Penicillin G 4 MU IV q4h OR Ampicillin 2 g IV q4h) AND Gentamicin 1–1.7 mg/kg IV q8h
- Fungi
- Preferred regimen: Amphotericin B 0.6–1.0 mg/kg IV q24h OR Amphotericin B liposomal 5 mg/kg/day IV q24h
References
- ↑ Tunkel, Allan R.; Hartman, Barry J.; Kaplan, Sheldon L.; Kaufman, Bruce A.; Roos, Karen L.; Scheld, W. Michael; Whitley, Richard J. (2004-11-01). "Practice guidelines for the management of bacterial meningitis". Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 39 (9): 1267–1284. doi:10.1086/425368. ISSN 1537-6591. PMID 15494903.
- ↑ Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.